10:04 AM EST - The Yield Growth Corp. : Announced its majority owned subsidiary NeonMind has entered into an agreement entitled "CLINICAL TRIALS START-UP STUDY AGREEMENT" with Translational Life Sciences Inc. to initiate clinical trials to test certain potential therapeutic effects of psilocybin and other compounds in psychedelic mushrooms. According to the terms of the engagement, signed on May 6, 2020, NeonMind and TLS shall work together to conduct the evaluation of psilocin or psilocybin on cravings, on the metabolism, on food addiction and on glucose and hormone levels. The Yield Growth Corp.
shares BOSS:CNX are trading unchanged at $0.16.
